Intra-peritoneal Chemotherapy in Ovarian Cancer

Neoplasms Clinical Trial

Official title:

Predictive Factors and Pharmacokinetics of Intra-peritoneal Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02861872
• Other study ID #: MOGYN16IP
• Status: Recruiting
• Phase: N/A
• First received: July 20, 2016
• Last updated: August 4, 2016
• Start date: July 2016
• Est. completion date: December 2017

Study information

• Verified date: July 2016
• Source: Radboud University
• Contact: Mark Rietveld, M.D. MSc.
• Phone: +31243610353
• Email: mark.rietveld[@]radboudumc.nl
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Observational

Clinical Trial Summary

Ovarian cancer is the third most common gynecological malignancy worldwide. Because of late, aspecific symptoms, the disease is usually diagnosed at an advanced stage. Most patients experience recurrence and die as a result of the disease within 5 years. Treatment is a combination of surgical debulking and systemic administered chemotherapy. Intra-peritoneal (IP) chemotherapy with is currently considered the most effective treatment. In patients with at least an optimal surgical debulking, this leads to an improvement in life expectancy from 50 to 66 months. IP administration of chemotherapeutic agents is still not common practice. Furthermore recent studies revealed that cancer cells express a variety of tumor antigens, which can be targeted by the immune system. Also ovarian cancer shows evidence of a role for the immune system in clinical outcome. Novel insights into the mechanism of action of chemotherapy indicate that the efficacy of chemotherapeutic interventions are dependent on the modulation of the immune system. The impression exists that since IP chemotherapy is used, relatively more recurrences outside the abdominal cavity are observed. As of yet, no studies have described pharmacokinetics and pharmacodynamics of IP administered cisplatin and paclitaxel in the blood circulation. The investigators propose to study the use of this aspiration fluid from the IP cavity as a biomarker for the efficacy of chemotherapy intervention, monitor the effect of chemotherapy on IP tumor cells in the peritoneal cavity and monitor the effect of chemotherapy on immune cells present in the IP cavity. As well the investigators propose to correlate the presence and amount of tumor cells in peritoneal fluid with the debulking efficacy and CA 125 levels. Secondary to this the investigators intend to determine the pharmacokinetics of cisplatin and paclitaxel when administered in the IP cavity in the central circulation (plasma) as well as in the peritoneal fluid. In this observational explorative study women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy are included. Immunological cell counts, tumor marker, immunological cell pathway activation and plasma concentrations of cisplatinum and paclitaxel in venous blood and in fluid aspirated from the abdominal cavity will be measured.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Patients receiving IP chemotherapy and therefore meeting the following criteria:

• Primary epithelial ovarian carcinoma FIGO stage III;

• Optimal or complete primary debulking (tumor rests = 1cm;

• WHO 0 - 2;

• Adequate hematological function: WBC = 3. 106/L en Platelets = 100. 106/L,

• Adequate renal function (Creatinine clearance >60 ml/min (Cockcroft))

• Adequate liver function tests (bilirubin and/or transaminases <1.25 UNL)

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study (according to the standard IP chemotherapy):

• Intestinal stoma proximal to the flexura lienalis;

• Postoperative sepsis after primary debulking;

• Haemoglobin < 6.0 mMol/L

• Extended intraperitoneal adhesions;

• Neurotoxicity grade>1;

• Previous chemotherapy for ovarian carcinoma;

• Symptomatic hearing loss;

• Age >70 years.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Effects of Chemotherapy
• Immune Tolerance
• Neoplasms
• Ovarian Neoplasms

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

References & Publications (4)

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. — View Citation

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Roche KL, Sonoda Y, Chi DS, O'Cearbhaill RE. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecol Oncol. 2016 Jul;142(1):13-8. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21. — View Citation

Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015 May 1;33(13):1460-6. doi: 10.1200/JCO.2014.55.9898. Epub 2015 Mar 23. Erratum in: J Clin Oncol. 2015 Nov 1;33(31):3678. — View Citation

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, Ananth CV, Neugut AI, Hershman DL. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. Obstet Gynecol. 2016 Jun;127(6):985-91. doi: 10.1097/AOG.0000000000001436. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary immunological endpoint: study the use of aspiration fluid from the IP cavity as a biomarker for the efficacy of chemotherapy intervention, measured by decrease in tumor cell count in IP fluid.		Change in tumor cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Primary	Primary pharmacokinetic endpoint: study pharmacokinetics of cisplatin (platinum unbound fraction) when administered in the IP cavity in plasma and in the peritoneal fluid.		Change in platinum unbound fraction of cisplatin during the first course (first three weeks) of chemotherapy.	No
Primary	Primary pharmacokinetic endpoint: study pharmacokinetics of paclitaxel (plasma concentrations) when administered in the IP cavity in plasma and in the peritoneal fluid.		Change in plasma concentration of paclitaxel during the first course (first three weeks) of chemotherapy.	No
Secondary	Secondary immunological endpoint: rise in dendritic cells		Change in dendritic cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: rise in tumor infiltrating lymphocytes		Change in lymphocyte cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: rise in natural killer cells		Change in natural killer cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherpy during 18 weeks	No
Secondary	Secondary immunological endpoint: decrease in macrophages M1 type		Change in macrophages M1 type cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: decrease in macrophages M2 type		Change in macrophages M2 type cell counts between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: change in cytokine level (IL-6) measured by ELISA		Change in IL-6 cytokine levels between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: change in cytokine level (IL-10) measured by ELISA		Change in IL-10 cytokine levels between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: change in cytokine level (IFNg) measured by ELISA		Change in IFNg cytokine levels between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: change in cytokine level (TNFa) measured by ELISA		Change in TNFa cytokine levels between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Secondary immunological endpoint: change in cytokine level (CCL2) measured by ELISA		Change in CCL2 cytokine levels between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No
Secondary	Primary immunological endpoint: study the use of aspiration fluid from the IP cavity as a biomarker for the efficacy of chemotherapy intervention, measured by decrease in pSTAT in IP fluid.		Change in pSTAT between samples 15 min before and after administration of chemotherapy through completion of chemotherapy during 18 weeks	No